Boehringer Ingelheim (BI) & Eli Lilly Reports RWE Results of Jardiance (empagliflozin) in EMPRISE study, Presented at AHA 2018

 Boehringer Ingelheim (BI) & Eli Lilly Reports RWE Results of Jardiance (empagliflozin) in EMPRISE study, Presented at AHA 2018

Boehringer Ingelheim (BI) & Eli Lilly Reports RWE Results of Jardiance (empagliflozin) in EMPRISE study, Presented at AHA 2018

Shots:  

  • The EMPRISE study involves assessing of Jardiance vs DPP-4 inhibitors in ~35,000 people with T2D initiated from 2014 to 2019, demonstrated 44% reduction in relative risk of hospitalization for HHF and was consistent in patients with or without CV diseases
  • The above results support finding from EMPA-REG OUTCOME trial assessing jardiance (10/25 mg qd) vs PBO in 7,000 patients in T2D patients with CV diseases, showed consistent results
  • Jardiance is indicated to lower blood sugar in adults with T2D and is also indicated to reduce CV deaths in adults. EMPRISE study is in collaboration with BI and Women’s Hospital

Click here to read full press release/ article | Ref: Eli Lilly | Image: News Times

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post